|
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
|
Jan 2019
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
|
May 2015
|
J Hematol Oncol
|
myelodysplastic syndromes (MDS)
|
|
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|
Nov 2016
|
N Engl J Med
|
myelodysplastic syndromes (MDS)
|
|
Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes
|
Jun 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes
|
Mar 2014
|
Expert Rev Anticancer Ther
|
myelodysplastic syndromes (MDS)
|
|
Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria
|
Jan 2018
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms
|
Mar 2014
|
Biol Blood Marrow Transplant
|
myelodysplastic syndromes (MDS)
|
|
To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia
|
Jun 2020
|
Haematologica
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia
|
Dec 2014
|
Hematology Am Soc Hematol Educ Program
|
myelodysplastic syndromes (MDS)
|
|
Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia
|
Dec 2014
|
Hematology Am Soc Hematol Educ Program
|
aplastic anemia
|
